Overview
At a Glance
Dulaglutide is a once-weekly GLP-1 receptor agonist sold as Trulicity, used primarily for type 2 diabetes. The REWIND trial demonstrated cardiovascular benefit even in patients without established heart disease, which distinguishes it in the GLP-1 class. It produces moderate weight loss (around 3–5 kg) but is not FDA-approved for obesity as a primary indication. It's well-tolerated overall, with the typical GLP-1 gastrointestinal side-effect profile.
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic molecule that mimics a naturally occurring gut hormone involved in blood sugar regulation, appetite, and digestion. Developed by Eli Lilly and Company, it is sold under the brand name Trulicity and is administered as a once-weekly subcutaneous injection for the treatment of type 2 diabetes.
Unlike semaglutide (which uses a fatty acid chain to extend its half-life) or liraglutide (which uses a similar acylation approach), dulaglutide uses a fundamentally different engineering strategy: it is a fusion protein — a modified GLP-1 analog covalently linked to a modified immunoglobulin G4 (IgG4) Fc fragment via a small peptide linker. This large molecular structure slows absorption from the injection site, resists enzymatic degradation, and reduces renal clearance, producing a half-life of approximately 5 days — long enough for once-weekly dosing (Grunberger et al., 2015).
Dulaglutide works through the same core GLP-1 receptor agonist mechanisms as other drugs in its class: it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the brain. However, its molecular weight (~63 kDa, compared to ~4.1 kDa for semaglutide) means it has limited ability to cross the blood-brain barrier, which may explain why it produces less weight loss than semaglutide at comparable receptor-activating doses.
The clinical evidence for dulaglutide is built primarily on the AWARD trial program (Assessment of Weekly AdministRation of LY2189265 in Diabetes), a series of Phase 3 trials that demonstrated its efficacy and safety across diverse type 2 diabetes populations. The REWIND trial (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) then demonstrated a 12% reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes, leading to an expanded FDA label for cardiovascular risk reduction (Gerstein et al., Lancet 2019).
Trulicity was one of the most widely prescribed GLP-1 receptor agonists globally before semaglutide's rise in market share. It remains a significant treatment option, particularly for patients who respond well to it, who are already stabilized on it, or whose insurance formularies favor it.
Quick Facts: Trulicity at a Glance
| Feature | Details |
|---|---|
| Generic name | Dulaglutide |
| Brand name | Trulicity |
| Manufacturer | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist (Fc fusion protein) |
| Route | Subcutaneous injection (single-dose pen) |
| Frequency | Once weekly |
| Available doses | 0.75 mg, 1.5 mg, 3 mg, 4.5 mg |
| FDA-approved for | Type 2 diabetes; cardiovascular risk reduction in T2D with established or multiple risk factors for CV disease |
| Not FDA-approved for | Weight management (as a standalone indication) |
| Avg HbA1c reduction | -1.1 to -1.6% (depending on dose and comparator) |
| Avg weight loss | ~2–5 kg (4–11 lbs) in diabetes trials |
| Common side effects | Nausea, diarrhea, vomiting, abdominal pain |
| Retail price | ~$950–1,000/month without insurance |
Sources: Trulicity FDA label; AWARD trial data; GoodRx.
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
When you eat, your gut releases GLP-1 (glucagon-like peptide-1) — a hormone that tells your pancreas to release insulin, slows digestion, and signals fullness. Natural GLP-1 is broken down by the enzyme DPP-4 within minutes. For a comprehensive review of GLP-1 biology, see Drucker, 2018 (Cell Metabolism).
Dulaglutide is engineered to last. But unlike semaglutide (which uses a fatty acid "tail" to hitch a ride on albumin), dulaglutide takes a completely different approach: it is a fusion protein. The molecule consists of two copies of a modified GLP-1 analog, each covalently linked to a modified human IgG4 Fc fragment via a small peptide linker (Grunberger et al., 2015).
The Fc Fusion Design
The engineering of dulaglutide involves several key modifications:
- GLP-1 analog modifications: The GLP-1 portion has amino acid substitutions at positions 8 (Gly→Aib) and 22 (Glu→Gly) that resist DPP-4 enzymatic breakdown while maintaining receptor binding affinity.
- IgG4 Fc fragment: The Fc portion (the "tail" of an antibody) is modified to reduce immune effector functions (Fc-gamma receptor binding and complement activation are minimized). This means the molecule uses the antibody structure for size and longevity, not for immune function.
- Peptide linker: A small (Gly₄Ser)₃ linker connects the GLP-1 analog to the Fc fragment, providing flexibility while maintaining biological activity.
- Result: A ~63 kDa homodimer that is too large for rapid renal clearance, resists DPP-4 degradation, and is recycled by FcRn (the neonatal Fc receptor) — the same mechanism that gives natural antibodies their long half-life. Dulaglutide's elimination half-life is approximately 5 days, supporting once-weekly dosing.
What Dulaglutide Does in the Body
Once injected, dulaglutide activates GLP-1 receptors throughout the body, producing multiple effects:
- Pancreas — insulin and glucagon: Enhances glucose-dependent insulin secretion (meaning it stimulates insulin only when blood sugar is elevated, reducing hypoglycemia risk). Simultaneously suppresses glucagon secretion, reducing hepatic glucose output.
- Stomach — gastric emptying: Slows the rate at which food moves from the stomach to the small intestine, producing earlier and longer-lasting satiety after meals.
- Brain — appetite regulation: Activates GLP-1 receptors in the hypothalamus and brainstem that regulate appetite and food intake. However, dulaglutide's large molecular size (~63 kDa) may limit its blood-brain barrier penetration compared to smaller GLP-1 RAs like semaglutide (~4.1 kDa), which could partially explain the more modest weight loss observed with dulaglutide (Brain GLP-1 and food intake regulation — PMC).
- Cardiovascular system: GLP-1 receptors are expressed in the heart and blood vessels. Activation appears to have anti-inflammatory and anti-atherosclerotic effects, which may contribute to the cardiovascular benefits demonstrated in the REWIND trial (Gerstein et al., Lancet 2019).
Key Pharmacological Differences from Other GLP-1 RAs
| Property | Dulaglutide (Trulicity) | Semaglutide (Ozempic/Wegovy) | Liraglutide (Victoza/Saxenda) |
|---|---|---|---|
| Half-life extension strategy | Fc fusion protein | Fatty acid acylation (albumin binding) | Fatty acid acylation (albumin binding) |
| Molecular weight | ~63 kDa | ~4.1 kDa | ~3.7 kDa |
| Half-life | ~5 days | ~7 days | ~13 hours |
| Dosing frequency | Once weekly | Once weekly | Once daily |
| GLP-1 receptor affinity | Lower (due to Fc bulk) | Higher | Moderate |
| BBB penetration | Limited (large molecule) | Greater (small, lipophilic) | Moderate |
Sources: Grunberger et al., 2015; Lau et al. — Discovery of Semaglutide; StatPearls: GLP-1 Receptor Agonists.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
FDA Approvals and Regulatory History
2014: Initial FDA Approval — Dulaglutide (Trulicity) was approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It launched at two doses: 0.75 mg and 1.5 mg, administered once weekly. The approval was based on the AWARD clinical trial program, which demonstrated superiority or non-inferiority to comparators including metformin, insulin glargine, exenatide, sitagliptin, and liraglutide across multiple patient populations (FDA label).
2020: Cardiovascular Risk Reduction Indication — Following the results of the REWIND trial, which showed a 12% reduction in major adverse cardiovascular events (MACE) in a broad population of patients with type 2 diabetes, the FDA expanded Trulicity's label to include reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors (Gerstein et al., Lancet 2019).
2020: Higher Doses Approved — The FDA approved two additional doses — 3 mg and 4.5 mg — for patients who needed additional glycemic control beyond what 1.5 mg provided. These higher doses were studied in the AWARD-11 trial and demonstrated further HbA1c reductions and modest additional weight loss (Frias et al., Lancet Diabetes Endocrinol 2021).
What Dulaglutide Is NOT Approved For
Dulaglutide does not have an FDA-approved indication for weight management. Unlike semaglutide (Wegovy) or liraglutide (Saxenda), Trulicity has not been submitted for or approved as a standalone weight loss medication. While weight loss is a documented secondary effect, Eli Lilly has focused its obesity drug development efforts on tirzepatide (Mounjaro/Zepbound) rather than pursuing a weight management indication for dulaglutide.
International Approvals
Dulaglutide is approved by the EMA (Europe), MHRA (UK), TGA (Australia), Health Canada, PMDA (Japan), and regulatory agencies across Asia, Latin America, and the Middle East. It is one of the most widely available GLP-1 receptor agonists globally. Approval timelines and specific indications vary by jurisdiction.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
All Uses: Approved, Off-Label, and Under Investigation
FDA-Approved Indications
| Indication | Details |
|---|---|
| Type 2 diabetes | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Can be used as monotherapy or combined with metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitors, or insulin. |
| Cardiovascular risk reduction | To reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. |
Source: Trulicity FDA label.
Common Off-Label Uses (Prescribed by Doctors)
These are uses where clinical evidence exists but the FDA hasn't formally approved dulaglutide for that specific indication. Doctors prescribe off-label when they judge the evidence supports it for a given patient.
| Use | Evidence Level | Reported in Medical Literature |
|---|---|---|
| Weight management | Moderate | AWARD trial data consistently shows weight loss of 2–5 kg as a secondary outcome. Some clinicians prescribe dulaglutide for weight management in patients who also have type 2 diabetes or prediabetes, though weight loss is less than with semaglutide. Reported in medical literature (Wysham et al., AWARD-1). |
| Prediabetes / diabetes prevention | Moderate | GLP-1 receptor agonists have been studied in prediabetes populations for delaying or preventing progression to type 2 diabetes. Reported in clinical practice guidelines (AACE/ACE 2016 guidelines). |
| Metabolic-associated steatotic liver disease (MASLD/NAFLD) | Preliminary–Moderate | GLP-1 receptor agonists as a class have shown improvements in liver fat and inflammation markers. Dulaglutide-specific data is limited compared to semaglutide, but improvements in liver enzymes have been documented in AWARD trial subanalyses (Seko et al., 2018). |
| Polycystic ovary syndrome (PCOS) | Preliminary | Small studies report improvements in metabolic parameters and androgen levels in women with PCOS and type 2 diabetes or insulin resistance treated with GLP-1 RAs. Reported in medical literature (Elkind-Hirsch et al., 2020). |
| Post-bariatric weight regain | Preliminary | GLP-1 receptor agonists are documented as adjunct therapy for weight regain following bariatric surgery. Dulaglutide has been used in this context when semaglutide is unavailable or not tolerated (Murvelashvili & Karanth, 2023). |
What Dulaglutide Is NOT Approved or Appropriate For
- Type 1 diabetes — Dulaglutide enhances insulin secretion from existing beta cells. In type 1 diabetes, those cells are destroyed. It does not replace insulin.
- Patients with personal/family history of medullary thyroid carcinoma or MEN 2 — Contraindicated due to the precautionary boxed warning.
- Patients with history of severe gastrointestinal disease — Including severe gastroparesis. Dulaglutide further delays gastric emptying.
- Pregnancy and breastfeeding — Discontinue at least 2 months before planned pregnancy. Animal studies showed adverse effects.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing: The Titration Schedule
The following reflects FDA-approved prescribing guidelines for reference. For complete prescribing information, see the official Trulicity FDA label. For detailed instructions on how to use the Trulicity pen, see the official Trulicity injection guide.
Trulicity Titration Schedule
| Step | Dose | Duration |
|---|---|---|
| Starting dose | 0.75 mg/week | At least 4 weeks |
| First escalation | 1.5 mg/week | At least 4 weeks (if additional control needed) |
| Second escalation | 3 mg/week | At least 4 weeks (if additional control needed) |
| Maximum dose | 4.5 mg/week | Maintenance |
Source: Trulicity FDA label.
Many patients achieve adequate glycemic control at 0.75 mg or 1.5 mg and do not require the higher doses. The 3 mg and 4.5 mg doses were added later based on AWARD-11 data showing incremental HbA1c improvements and modest additional weight loss at higher doses (Frias et al., Lancet Diabetes Endocrinol 2021).
How Trulicity Is Used
The following describes the administration method per FDA-approved labeling and manufacturer instructions. Always follow your prescribing physician's specific guidance.
Trulicity comes as a prefilled, single-dose pen with a hidden, pre-attached needle. There is no mixing, no reconstitution, no dose dialing — each pen delivers one fixed dose.
- Needle: Pre-attached and hidden within the pen. Most patients describe the injection as a brief click followed by a pinch or pressure. The needle is never visible during normal use.
- Injection sites: Abdomen (at least 2 inches from navel), front of thigh, or upper arm. Rotate sites each week.
- Frequency: Once weekly, same day each week. Can be given at any time of day, with or without meals.
- Day flexibility: The injection day can be changed, as long as the last dose was administered 3 or more days (72+ hours) before.
- Missed dose: If a dose is missed, administer it as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. If less than 3 days remain, skip the missed dose.
- Storage: Refrigerate (36–46°F / 2–8°C) before first use. Each single-dose pen can be kept at room temperature (up to 86°F / 30°C) for up to 14 days. Do not freeze.
- Administration technique: Your healthcare provider or pharmacist will demonstrate proper use at your first appointment. For detailed instructions, refer to the official Trulicity injection guide.
Dose Adjustments with Concomitant Medications
- Insulin or sulfonylureas: When starting dulaglutide in patients already taking insulin or a sulfonylurea, consider reducing the dose of insulin or sulfonylurea to reduce hypoglycemia risk.
- Oral medications: Because dulaglutide slows gastric emptying, it may affect the absorption of some oral medications. Patients taking medications with a narrow therapeutic index should be monitored.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What the Data Shows
AWARD Trial Program — Diabetes Results
The AWARD program comprised multiple Phase 3 randomized controlled trials evaluating dulaglutide across diverse type 2 diabetes populations and comparators.
| Trial | Comparator | Participants | Duration | HbA1c Change (1.5 mg) | Weight Change (1.5 mg) |
|---|---|---|---|---|---|
| AWARD-1 | Exenatide 10 µg BID, placebo | 978 | 52 weeks | -1.51% | -1.30 kg |
| AWARD-2 | Insulin glargine | 807 | 78 weeks | -1.08% | -1.87 kg |
| AWARD-3 | Metformin (monotherapy) | 807 | 52 weeks | -0.78% | -2.29 kg |
| AWARD-4 | Insulin glargine (+ prandial insulin) | 884 | 52 weeks | -1.64% | -0.87 kg |
| AWARD-5 | Sitagliptin | 1,098 | 52 weeks | -1.10% | -3.03 kg |
| AWARD-6 | Liraglutide 1.8 mg | 599 | 26 weeks | -1.42% | -2.90 kg |
| AWARD-10 | Placebo (add-on to SGLT2i) | 424 | 24 weeks | -1.34% | -3.10 kg |
| AWARD-11 | Dulaglutide 1.5 mg | 1,842 | 36 weeks | -1.71% (4.5 mg) | -4.67 kg (4.5 mg) |
Sources: AWARD trials as cited. HbA1c and weight changes are mean change from baseline for the dulaglutide arm.
Key finding from AWARD-6: Dulaglutide 1.5 mg was non-inferior to liraglutide 1.8 mg for HbA1c reduction, establishing it as a competitive once-weekly alternative to daily liraglutide.
REWIND Trial — Cardiovascular Outcomes
The REWIND trial was a landmark cardiovascular outcomes trial that enrolled 9,901 patients with type 2 diabetes who had either established cardiovascular disease or cardiovascular risk factors. Notably, REWIND had a broader patient population than most cardiovascular outcomes trials — only 31% of participants had established cardiovascular disease at baseline (compared to 83% in the semaglutide SELECT trial), making the results more generalizable to typical type 2 diabetes patients.
| Outcome | Dulaglutide 1.5 mg | Placebo | Hazard Ratio |
|---|---|---|---|
| Primary composite MACE | 12.0% | 13.4% | 0.88 (95% CI: 0.79–0.99; p=0.026) |
| Non-fatal stroke | 2.7% | 3.5% | 0.76 (0.61–0.95) |
| Non-fatal MI | 4.1% | 4.3% | 0.96 (0.79–1.16) |
| CV death | 5.4% | 5.8% | 0.91 (0.78–1.06) |
Source: Gerstein et al., Lancet 2019. Median follow-up: 5.4 years.
The 12% MACE reduction was driven primarily by a 24% reduction in non-fatal stroke — a particularly notable finding. The trial's long duration (median 5.4 years) and broad population added significant strength to the evidence. A pre-specified subanalysis showed that the cardiovascular benefit was consistent regardless of whether patients had established cardiovascular disease at baseline (Gerstein et al., Lancet Diabetes Endocrinol 2020).
Weight Loss: Context and Expectations
Dulaglutide produces modest weight loss compared to semaglutide or tirzepatide. Across the AWARD trials, patients on dulaglutide 1.5 mg lost approximately 1–3 kg (2–7 lbs) on average. At the higher 4.5 mg dose (AWARD-11), weight loss increased to approximately 4.7 kg (~10 lbs).
For context, semaglutide 2.4 mg (Wegovy) produces average weight loss of ~15% of body weight in non-diabetic patients. Dulaglutide's weight loss is significantly more modest, which is why it is not positioned or approved as a weight management medication. Patients seeking substantial weight loss are generally directed toward semaglutide or tirzepatide.
Further Reading
- AWARD-1 — Dulaglutide vs. Exenatide (Diabetes Care)
- AWARD-5 — Dulaglutide vs. Sitagliptin (Diabetes Care)
- REWIND — Dulaglutide Cardiovascular Outcomes (Lancet)
- REWIND Subanalysis — CV Benefit by Baseline Risk (Lancet Diabetes Endocrinol)
- AWARD-11 — Higher-Dose Dulaglutide (Lancet Diabetes Endocrinol)
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
Common Side Effects by Dose
The following table reflects data from the AWARD clinical trials and the FDA prescribing information.
| Side Effect | 0.75 mg | 1.5 mg | Placebo |
|---|---|---|---|
| Nausea | 12.4% | 21.1% | 5.3% |
| Diarrhea | 8.9% | 12.6% | 5.3% |
| Vomiting | 6.0% | 12.7% | 2.3% |
| Abdominal pain | 6.5% | 9.4% | 4.9% |
| Decreased appetite | 4.9% | 8.6% | 1.6% |
| Dyspepsia | 4.1% | 5.8% | 2.3% |
| Fatigue | 4.2% | 5.6% | 2.1% |
| Discontinuation due to AEs | 3.4% | 5.9% | 1.6% |
Source: Trulicity FDA label, AWARD pooled data.
Higher-Dose Side Effects (3 mg and 4.5 mg — AWARD-11)
| Side Effect | 3 mg | 4.5 mg | 1.5 mg |
|---|---|---|---|
| Nausea | 15.5% | 16.9% | 11.5% |
| Diarrhea | 11.3% | 13.2% | 7.9% |
| Vomiting | 6.6% | 8.8% | 4.4% |
| Decreased appetite | 7.1% | 8.1% | 3.9% |
| Discontinuation due to GI AEs | 3.0% | 4.2% | 1.5% |
Source: AWARD-11 (Frias et al.).
Gastrointestinal Effects: What to Know
GI side effects with dulaglutide are generally milder than with semaglutide at comparable doses. Most nausea occurs during the first 2–4 weeks of treatment and during dose escalation. The gradual titration schedule exists specifically to minimize these effects.
Management strategies documented in clinical practice:
- Eat smaller meals — large portions with delayed gastric emptying are the primary nausea trigger
- Avoid high-fat and greasy foods during dose escalation
- Stay hydrated — dehydration from vomiting or diarrhea worsens symptoms
- Slower titration — some clinicians extend time at each dose level for patients with significant GI intolerance
Serious but Rare Side Effects
In rodent studies, dulaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (including medullary thyroid carcinoma) at clinically relevant exposures. It is unknown whether dulaglutide causes thyroid C-cell tumors in humans. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Key context: The C-cell response appears to be rodent-specific. Human thyroid C-cells express very low levels of GLP-1 receptors compared to rodents. Over 15+ years of GLP-1 RA use in humans, no clear signal of increased MTC risk has emerged in pharmacovigilance data (Bjerre Knudsen et al.; Hegedüs et al. review).
- Pancreatitis: Acute pancreatitis has been reported in clinical trials and post-marketing. Patients should be monitored for signs (severe abdominal pain radiating to the back, with or without vomiting). If pancreatitis is suspected, dulaglutide should be discontinued and not restarted.
- Gallbladder disease: GLP-1 receptor agonists are associated with increased risk of cholelithiasis (gallstones) and cholecystitis, likely related to both weight loss and direct effects on gallbladder motility (He et al., JAMA 2022).
- Acute kidney injury: Reported, usually secondary to dehydration from severe GI side effects. Patients with existing kidney disease should be monitored closely.
- Hypersensitivity reactions: Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported. Discontinue if suspected and do not rechallenge.
- Hypoglycemia: Low risk when used alone (glucose-dependent mechanism). Risk increases when combined with insulin or sulfonylureas — dose reduction of those medications is usually needed.
- Increased heart rate: Small mean increases in resting heart rate (2–4 beats per minute) have been observed across trials, consistent with the GLP-1 RA class effect.
Injection Site Reactions
Injection site reactions (redness, itching, rash at the injection site) were reported in approximately 0.5–1% of patients in clinical trials. Rotating injection sites helps prevent this. Trulicity's hidden-needle pen design generally results in less injection-site anxiety compared to traditional syringe-based delivery.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Ongoing Research
Cardiovascular Protection: REWIND and Beyond
The REWIND trial remains one of the most important cardiovascular outcomes trials in the GLP-1 RA class for several reasons:
- Broadest population: Only 31% of REWIND participants had established cardiovascular disease — the rest had risk factors only. This makes the results applicable to a much broader T2D population than trials like SELECT (semaglutide) or LEADER (liraglutide), which enrolled predominantly patients with established CV disease.
- Longest follow-up: Median follow-up of 5.4 years was longer than most GLP-1 RA cardiovascular trials, providing more durable outcome data.
- Stroke reduction: The 24% reduction in non-fatal stroke was a standout finding. Subsequent analyses are investigating whether this reflects anti-atherosclerotic effects, anti-inflammatory mechanisms, or improvements in metabolic risk factors.
Subanalyses of REWIND continue to generate insights into how GLP-1 receptor agonism affects cardiovascular risk across different patient subgroups, including by age, sex, baseline HbA1c, and renal function (Gerstein et al., Lancet Diabetes Endocrinol 2020).
Kidney Outcomes
A pre-specified secondary analysis of REWIND showed that dulaglutide reduced the composite renal outcome (new macroalbuminuria, sustained decline in eGFR of ≥30%, or chronic renal replacement therapy) by 15% compared to placebo. The effect was primarily driven by a reduction in new macroalbuminuria (Gerstein et al., Lancet Diabetes Endocrinol 2019 — renal outcomes). This finding contributed to the broader understanding of GLP-1 RAs as renoprotective agents and informed the design of the FLOW trial (which tested semaglutide for CKD).
Cognitive Outcomes
REWIND included a pre-specified cognitive substudy (REWIND-MIND) that assessed the effect of dulaglutide on cognitive function in older adults with type 2 diabetes. Results showed that dulaglutide was associated with a reduced rate of cognitive decline as measured by the Montreal Cognitive Assessment (MoCA) and the Digit Symbol Substitution Test (DSST) over the 5.4-year follow-up period (Cukierman-Yaffe et al., Lancet Neurol 2020). While this is a secondary endpoint and hypothesis-generating, it adds to the growing evidence that GLP-1 RAs may have neuroprotective effects.
Dulaglutide in the Broader GLP-1 RA Landscape
Eli Lilly's current drug development focus has shifted from dulaglutide to tirzepatide (Mounjaro/Zepbound) — a dual GIP/GLP-1 receptor agonist that produces substantially greater weight loss and glycemic improvement than any single-agonist GLP-1 RA. Tirzepatide has effectively replaced dulaglutide as Lilly's flagship incretin-based therapy.
Active research involving dulaglutide is now primarily in the areas of:
- Real-world evidence studies — Long-term outcomes data from patients who have been on dulaglutide for 5+ years
- Comparative effectiveness — Head-to-head analyses of dulaglutide vs. newer agents (semaglutide, tirzepatide) in real-world populations
- Biosimilar development — Multiple companies are developing biosimilar versions of dulaglutide as patent protections begin to expire
- Class-level meta-analyses — REWIND data continues to be pooled with other GLP-1 RA trials to assess class-wide cardiovascular, renal, and neurological effects
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost & Access
Retail Pricing (Without Insurance)
| Dose | List Price / Month | Notes |
|---|---|---|
| 0.75 mg (4 pens) | ~$950–1,000 | Starting dose. Single-dose pens, once weekly. |
| 1.5 mg (4 pens) | ~$950–1,000 | Most commonly prescribed maintenance dose. |
| 3 mg (4 pens) | ~$950–1,000 | Higher dose for additional glycemic control. |
| 4.5 mg (4 pens) | ~$950–1,000 | Maximum dose. |
Sources: GoodRx. Prices fluctuate; check current pricing at your pharmacy.
Insurance Coverage
Commercial Insurance
- For type 2 diabetes: Generally covered with prior authorization. Typical copay: $25–150/month depending on plan tier and formulary placement.
- Prior authorization requirements: Usually requires documented HbA1c, and in many cases, trial of metformin and/or another second-line agent before GLP-1 RA approval.
- Formulary competition: Insurance formularies may prefer one GLP-1 RA over others based on negotiated pricing. Some plans favor Trulicity; others favor Ozempic or Victoza. If your plan doesn't cover Trulicity, your physician can often submit a formulary exception request.
Medicare Part D
- Covered for type 2 diabetes under Part D. Formulary tier placement varies by plan — may be Tier 3 (preferred brand) or Tier 4 (non-preferred brand).
- Medicare patients are not eligible for manufacturer copay savings cards.
Medicaid
- Coverage varies by state. Most state Medicaid programs cover at least one GLP-1 RA for type 2 diabetes, but formulary preferences differ.
Eli Lilly Savings Programs
- Trulicity Savings Card: For commercially insured patients, may reduce copay to as low as $25/month. Not available for Medicare, Medicaid, or government-insured patients. Eligibility requirements apply. Check Trulicity.com for current offers.
- Lilly Cares Patient Assistance Program: For uninsured patients or those who meet income eligibility requirements. Provides medication at no cost. Application through healthcare provider required. See LillyCares.com for details.
Trulicity vs. Other GLP-1 RAs: Cost Context
At ~$950–1,000/month, Trulicity's retail price is comparable to Ozempic (~$935/month) and less expensive than Wegovy (~$1,350/month). However, effective out-of-pocket cost depends entirely on insurance coverage, formulary tier, and available savings programs. For many commercially insured patients with type 2 diabetes, the actual monthly cost is $25–150 regardless of which GLP-1 RA their plan covers.
As biosimilar dulaglutide products enter development, future pricing may decrease. However, biosimilar biologics typically launch at 15–30% discounts (not the 80–90% discounts seen with generic small-molecule drugs), so dramatic price reductions are not guaranteed.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Myth: Dulaglutide is basically the same as semaglutide.
Answer: Dulaglutide and semaglutide are both GLP-1 receptor agonists, but they are structurally and pharmacologically distinct. Dulaglutide is a large Fc fusion protein (~63 kDa) that achieves its long half-life through its antibody-like structure. Semaglutide is a small acylated peptide (~4.1 kDa) that uses fatty acid binding to albumin. These structural differences translate to meaningful clinical differences: semaglutide produces substantially more weight loss (likely due to greater blood-brain barrier penetration), has a longer half-life (7 days vs. 5 days), and at higher doses achieves somewhat greater HbA1c reductions. Both are effective GLP-1 RAs, but they are not interchangeable.
Myth: Trulicity doesn't help with weight loss.
Answer: Trulicity does produce weight loss — it's just more modest than semaglutide or tirzepatide. Across the AWARD trials, patients on dulaglutide 1.5 mg lost an average of 1–3 kg. At 4.5 mg (AWARD-11), weight loss averaged ~4.7 kg. While this is meaningful, it's not in the same range as semaglutide 2.4 mg (~15% body weight) or tirzepatide 15 mg (~20% body weight). Trulicity is appropriately positioned as a diabetes medication with a secondary weight benefit, not as a weight management drug (AWARD-11).
Myth: Trulicity causes thyroid cancer.
Answer: This is a misinterpretation of the boxed warning. Dulaglutide carries a precautionary warning about thyroid C-cell tumors based on rodent studies. Human thyroid C-cells express very low levels of GLP-1 receptors compared to rodents, and over 15+ years of GLP-1 RA use in humans, no clear signal of increased medullary thyroid carcinoma risk has emerged. The warning remains as a precaution, and dulaglutide is contraindicated in patients with personal or family history of MTC or MEN 2 (Bjerre Knudsen et al.).
Myth: If I'm already on Trulicity, there's no reason to switch to a newer drug.
Answer: If Trulicity is providing adequate glycemic control with tolerable side effects, there may be no clinical reason to switch. However, patients who need greater HbA1c reduction, more significant weight loss, or who have developed cardiovascular disease may benefit from discussing semaglutide or tirzepatide with their provider. Switching should always be a conversation between patient and physician, based on individual goals and clinical response.
Myth: The hidden needle pen is just a marketing gimmick.
Answer: Needle phobia (trypanophobia) affects an estimated 20–30% of adults and is a documented barrier to injectable medication adherence. Trulicity's hidden-needle pen design was specifically engineered to address this: the patient never sees the needle before, during, or after injection. Clinical studies have shown that device design significantly impacts patient preference and adherence to injectable therapies. This is a clinically meaningful design feature, particularly for patients initiating their first injectable medication.
Myth: GLP-1 drugs are just for people who are lazy and don't want to exercise.
Answer: Type 2 diabetes is a complex metabolic disease driven by insulin resistance, beta-cell dysfunction, and dysregulated incretin signaling — not laziness. Dulaglutide addresses the biological mechanisms of the disease: it enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying. The REWIND trial demonstrated that dulaglutide reduces cardiovascular events by 12% — a cardiovascular protective effect that exercise alone has not been demonstrated to achieve in a randomized trial of this scale. Pharmacological treatment of chronic metabolic disease is standard medical practice (REWIND trial).
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
The evidence clearly shows:
- HbA1c reductions of 1.1–1.6% across the AWARD trial program, with the 4.5 mg dose producing reductions up to 1.7% — competitive with other GLP-1 RAs for glycemic control
- 12% reduction in major adverse cardiovascular events (MACE) in the REWIND trial, with a notable 24% reduction in non-fatal stroke — demonstrated in a broad population including patients without established cardiovascular disease (REWIND trial)
- Modest weight loss of 1–5 kg depending on dose — meaningful for metabolic health but significantly less than semaglutide or tirzepatide
- 15% reduction in renal composite outcomes — adding to the evidence that GLP-1 RAs have kidney-protective effects
- Evidence of reduced cognitive decline in the REWIND-MIND substudy — hypothesis-generating but consistent with the broader GLP-1 RA neuroprotection research
- Manageable side effect burden: GI side effects affect 8–22% of users (generally milder than semaglutide), with ~4–6% discontinuing due to adverse events
- Convenient delivery: Once-weekly, single-dose, hidden-needle pen — designed for ease of use and reduced injection anxiety
- Cost: ~$950–1,000/month at retail, with savings programs available for commercially insured patients
Dulaglutide (Trulicity) is an established, well-studied GLP-1 receptor agonist with strong evidence for glycemic control and cardiovascular protection in type 2 diabetes. While newer agents (semaglutide, tirzepatide) offer greater weight loss and, in some cases, greater glycemic efficacy, dulaglutide remains a viable treatment option — particularly for patients who are already well-controlled on it, whose insurance formularies favor it, or who respond well to its specific pharmacological profile.
The decision to start, continue, or switch from dulaglutide involves weighing individual treatment goals, side effect tolerance, cardiovascular risk profile, weight management needs, and insurance coverage — with guidance from a qualified healthcare provider.
Questions to Discuss With Your Clinician
- Is dulaglutide the right GLP-1 RA for my specific clinical profile, or would another agent be more appropriate?
- What dose should I start at, and what is the plan for titration?
- How will we monitor for cardiovascular and renal benefits over time?
- Should I consider switching to semaglutide or tirzepatide for greater weight loss or glycemic control?
- What does my insurance cover, and what savings programs are available?
- How should my insulin or sulfonylurea doses be adjusted?
- Are there interactions with my current medications?
- If I plan to become pregnant, when should I stop?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
GLP-1 Biology & Mechanism of Action
- Drucker (2018) — "Mechanisms of Action and Therapeutic Application of GLP-1" — Cell Metabolism
- StatPearls: Glucagon-Like Peptide-1 Receptor Agonists — Class Overview
- Brain GLP-1 and the Regulation of Food Intake — PMC
Dulaglutide Molecular Design & Pharmacology
- Grunberger et al. (2015) — "Dulaglutide: A Review in Type 2 Diabetes" — PMC
- Lau et al. — "The Discovery and Development of Liraglutide and Semaglutide" — PMC
FDA Prescribing Information
AWARD Clinical Trials
- AWARD-1 — Wysham et al. — Dulaglutide vs. Exenatide (Diabetes Care, 2014)
- AWARD-2 — Giorgino et al. — Dulaglutide vs. Insulin Glargine (Diabetes Care, 2015)
- AWARD-3 — Umpierrez et al. — Dulaglutide Monotherapy vs. Metformin (Diabetes Care, 2014)
- AWARD-4 — Blonde et al. — Dulaglutide vs. Insulin Glargine + Prandial Insulin (Lancet, 2015)
- AWARD-5 — Nauck et al. — Dulaglutide vs. Sitagliptin (Diabetes Care, 2014)
- AWARD-6 — Dungan et al. — Dulaglutide vs. Liraglutide (Lancet, 2014)
- AWARD-10 — Ludvik et al. — Dulaglutide Add-on to SGLT2i (Lancet Diabetes Endocrinol, 2018)
- AWARD-11 — Frias et al. — Higher-Dose Dulaglutide (Lancet Diabetes Endocrinol, 2021)
REWIND Trial & Cardiovascular Outcomes
- Gerstein et al. (2019) — "Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND)" — Lancet
- Gerstein et al. (2020) — "REWIND Subanalysis: Cardiovascular Benefit by Baseline Risk" — Lancet Diabetes Endocrinol
- Gerstein et al. (2019) — "REWIND Renal Outcomes" — Lancet Diabetes Endocrinol
- Cukierman-Yaffe et al. (2020) — "REWIND-MIND: Dulaglutide and Cognitive Decline" — Lancet Neurol
Safety & Side Effects
- He et al. (JAMA 2022) — "GLP-1 RA Use and Risk of Gallbladder and Biliary Diseases"
- Bjerre Knudsen et al. — "C-Cell Effects in Mice Are Mediated via GLP-1 Receptor"
- Review of GLP-1 RA Association with Thyroid C-Cell Tumors
Off-Label Uses
- Seko et al. (2018) — GLP-1 RAs and Liver Disease
- Elkind-Hirsch et al. (2020) — GLP-1 RAs in PCOS
- Murvelashvili & Karanth (2023) — GLP-1 RAs for Post-Bariatric Weight Regain
- AACE/ACE 2016 Clinical Practice Guidelines for Obesity
Pricing & Access
- GoodRx: Trulicity Pricing and Coupons
- Trulicity Savings Card (Eli Lilly)
- Lilly Cares Patient Assistance Program
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
